William Young (Thomas Jefferson University, Philadelphia, USA) discusses the most important developments in migraine prevention and treatment, and his roles as Past President of the Alliance for Headache Disorders Advocacy and President of Miles For Migraine.
1. What do you consider the most important developments in migraine prevention and treatment in the last year? (0:04)
2. What is a Chiari malformation headache and how can it be recognized? (0:45)
3. What is your opinion on the use of cannabinoids in the treatment of migraine? (1:44)
4. Could you tell us a little about your role as Past President of the Alliance for Headache Disorders Advocacy and President of Miles For Migraine? (2:25)
5. How can our choice of words improve understanding and empathy for people with migraine? (3:41)
Speaker disclosure: William Young has nothing to disclose in relation to this video interview.
Filmed at the American Academy of Neurology (AAN) Annual Meeting, Philadelphia, USA, May 2019.
Share this Video
Related Videos In Headache Disorders
Serena Orr, AHS 2021: Stress and Peak Pain Severity in Chronic Migraine
We had the great pleasure of meeting with Dr. Serena Orr (Hotchkiss Brain Institute, University of Calgary, Calgary, Canada) to discuss the relationship between peak pain severity in chronic migraine, and its relationship to stress. The abstract ‘The Relationship Between Perceived Stress and Peak Pain Severity in Individuals with Chronic Migraine: A Longitudinal Cohort Study […]
Jessica Ailani, EAN 2021: Phase 3b CONQUER Trial Results
It was a great pleasure to meet with Jessica Ailani (MedStar Georgetown, Georgetown University Hospital, Pasquerilla Healthcare Center, Washington, WA, USA) to discuss the impact of galcanezumab on migraine care in the phase 3b CONQUER trial. The abstract entitled: ‘Total pain burden in patients with treatment-resistant migraine: effects of galcanezumab in the CONQUER Phase 3b […]
Michael Marmura, AHS 2021: Intranasal Ketamine for the Treatment of Refractory Headache
touchNEUROLOGY met with Michael Marmura (Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA) to discuss his study investigating intranasal ketamine for the treatment of refractory headache. The abstract ‘Intranasal Ketamine for Refractory Headache’ was presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting 2021, 3-6 June 2021. Questions: What is the rationale […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!